

Haematologica  
HAEMATOL/2017/163790  
Version 3

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions  
in the allelic burden of concurrent CSF3R mutations in chronic  
neutrophilic leukemia

Arief S. Gunawan, Donal P. McLornan, Bridget Wilkins, Katherine  
Waghorn, Yvette Hoade, Nick C. P. Cross, and Claire N. Harrison

Disclosures: Professors Harrison and Cross received research support, honoraria, and speaker fees from Novartis. Dr McLornan received speaker fees from Novartis. All other authors declare no conflict of interest.

Contributions: ASG and DM wrote the manuscript. BW reviewed the histology. KW and YH carried out the genetic analyses. NCPC and CH supervised the study.